Germline Neurofibromin 1 mutation enhances the anti‐tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity

Abstract

Summary Juvenile myelomonocytic leukaemia (JMML) is an aggressive paediatric leukaemia characterized by mutations in five canonical RAS pathway genes, including the NF1 gene. JMML is driven by germline NF1 gene mutations, with additional somatic aberrations resulting in the NF1 biallelic inactivation, leading to disease progression. Germline mutations in the NF1 gene alone primarily cause benign neurofibromatosis type 1 (NF1) tumours rather than malignant JMML, yet the underlying mechanism remains unclear. Here, we demonstrate that with reduced NF1 gene dose, immune cells are promoted in anti‐tumour immune response. Comparing the biological properties of JMML and NF1 patients, we found that not only JMML but also NF1 patients driven by NF1 mutations could increase monocytes generation. But monocytes cannot further malignant development in NF1 patients. Utilizing haematopoietic and macrophage differentiation from iPSCs, we revealed that NF1 mutations or knockout (KO) recapitulated the classical haematopoietic pathological features of JMML with reduced NF1 gene dose. NF1 mutations or KO promoted the proliferation and immune function of NK cells and iMacs derived from iPSCs. Moreover, NF1‐mutated iNKs had a high capacity to kill NF1‐KO iMacs. NF1‐mutated or KO iNKs administration delayed leukaemia progression in a xenograft animal model. Our findings demonstrate that germline NF1 mutations alone cannot directly drive JMML development and suggest a potential cell immunotherapy for JMML patients.

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

“…As a new way to treat tumors with immunotherapy, mannose-modified lipid calcium phosphate nanoparticle vaccine has shown great promise in improving the immune response to tumors and building immune memory [231][232][233][234][235]. This provides new ideas and strategies for the future treatment of cancer and is expected to play an important role in clinical practice, bringing more effective treatment effects and a better quality of life for patients [236][237][238][239][240].…”

Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges

“…In contrast, germline mutations are inherited changes that affect reproductive cells and are present in all somatic cells; they may be common or rare in a given population. Of note, not only are somatic variants important for cancer treatment and mainly used as molecular targets, but germline mutations may also contribute, at least in part, to tumor development, progression, and resistance ( Chen X et al, 2023 ; Wang et al, 2023 ).…”